Nina Schöbi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nina Schöbi has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Duppenthaler
Division of Pediatric Infectious Disease, Department of Pediatrics, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland, unibe.ch
5 shared publications Christoph Aebi
Division of Paediatric Infectious Disease, Department of Paediatrics, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland
3 shared publications- Christoph Aebi
Division of Paediatric Infectious Diseases, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
3 shared publications - Matthias Volkmar Kopp
Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
3 shared publications - Philipp Agyeman
Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern
3 shared publications Andrea Duppenthaler
Division of Paediatric Infectious Disease, Department of Paediatrics, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland
2 shared publications
Latest Publications
- Open Access
- 29 May 2026
- Published by Springer Nature in Intensive Care Medicine – Paediatric and Neonatal
- Vol. 4 (1) , 21
International survey on immunological diagnostics in children with sepsis
Background: Sepsis is a leading cause of death and disability in children and it affects in up to 50% previously healthy children who have access to health care. Undiagnosed inborn error of immunity, considered to be rare at population level, may underlie host immune dysregulation and result in exceptionally high risk for life-threatening infections. Methods: From May 2023 to March 2024, physicians involved in the care of children with sepsis were questioned regarding their follow-up investigation practice in paediatric patients after community-acquired sepsis. This survey was distributed through three international societies. Results: A total of 168 responses from 50 countries were analysed. The majority (82%), reported to have more than 10 years of experience. More than half (53%) stated to work in Paediatric Infectious Diseases. Major variability across respondents was observed in the approach to different scenarios of patients with sepsis. Severity of presentation, and unusual presentations increased the likelihood of ordering immunological investigations. Only 7% reported to have access to a standardised sepsis specific guideline to immunologically investigate paediatric patients after sepsis. Conclusion: The results of this survey highlight a broad range of practices surrounding immunological investigations of children with sepsis. A consensus-based algorithm for standardised immunological and genetic testing in paediatric patients after sepsis could guide practice and inform future studies in the field.
- 29 May 2026
- Published by Springer Nature in Intensive Care Medicine – Paediatric and Neonatal
- Vol. 4 (1) , 21
Open AccessInternational survey on immunological diagnostics in children with sepsis
Background: Sepsis is a leading cause of death and disability in children and it affects in up to 50% previously healthy children who have access to health care. Undiagnosed inborn error of immunity, considered to be rare at population level, may underlie host immune dysregulation and result in exceptionally high risk for life-threatening infections. Methods: From May 2023 to March 2024, physicians involved in the care of children with sepsis were questioned regarding their follow-up investigation practice in paediatric patients after community-acquired sepsis. This survey was distributed through three international societies. Results: A total of 168 responses from 50 countries were analysed. The majority (82%), reported to have more than 10 years of experience. More than half (53%) stated to work in Paediatric Infectious Diseases. Major variability across respondents was observed in the approach to different scenarios of patients with sepsis. Severity of presentation, and unusual presentations increased the likelihood of ordering immunological investigations. Only 7% reported to have access to a standardised sepsis specific guideline to immunologically investigate paediatric patients after sepsis. Conclusion: The results of this survey highlight a broad range of practices surrounding immunological investigations of children with sepsis. A consensus-based algorithm for standardised immunological and genetic testing in paediatric patients after sepsis could guide practice and inform future studies in the field.
- 29 May 2026
- Published by Springer Nature
- p. 123-161
Infektiologie
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2026 (1)
Management of Coxiella burnetii Endocarditis in a Child With Congenital Heart Disease
A 6‐year‐old male patient with pulmonary atresia and recent valve replacement with a Melody valve presented with a 6‐week history of fever and cough. He was diagnosed with Coxiella burnetii endocarditis based on a C. burnetii Phase I IgG antibody titre of 1:65,536 and increased metabolic activity surrounding his prosthetic cardiac valve on positron emission tomography scan. Treatment was initiated with doxycycline and hydroxychloroquine. However, despite dose escalation, target plasma concentrations were not achieved. The patient experienced rapid clinical improvement, and serological markers declined gradually. Antimicrobial therapy was discontinued after 40 months, as predefined serological criteria were met, clinical course was favourable, and a follow‐up positron emission tomography scan demonstrated a significant reduction in metabolic activity around the prosthetic valve. Up to 23 months after cessation of therapy, the patient showed no evidence of active C. burnetii endocarditis during follow‐up. The Melody valve maintained its function, and valve replacement was not required. Clinicians should employ an individualised treatment approach to children with C. burnetii endocarditis.
- 1 January 2026
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2026 (1)
Open AccessManagement of Coxiella burnetii Endocarditis in a Child With Congenital Heart Disease
A 6‐year‐old male patient with pulmonary atresia and recent valve replacement with a Melody valve presented with a 6‐week history of fever and cough. He was diagnosed with Coxiella burnetii endocarditis based on a C. burnetii Phase I IgG antibody titre of 1:65,536 and increased metabolic activity surrounding his prosthetic cardiac valve on positron emission tomography scan. Treatment was initiated with doxycycline and hydroxychloroquine. However, despite dose escalation, target plasma concentrations were not achieved. The patient experienced rapid clinical improvement, and serological markers declined gradually. Antimicrobial therapy was discontinued after 40 months, as predefined serological criteria were met, clinical course was favourable, and a follow‐up positron emission tomography scan demonstrated a significant reduction in metabolic activity around the prosthetic valve. Up to 23 months after cessation of therapy, the patient showed no evidence of active C. burnetii endocarditis during follow‐up. The Melody valve maintained its function, and valve replacement was not required. Clinicians should employ an individualised treatment approach to children with C. burnetii endocarditis.
- Open Access
- 14 October 2025
- Published by Springer Nature in Infection
- Vol. 54 (1) , 287-297
Paediatric parapneumonic effusion – a twenty-year clinical narrative
Purpose: Paediatric parapneumonic effusion (PPE) is accompanied by an increased risk of complications, e.g., sepsis or lung sequelae. Treatment strategies span from antibiotics alone to surgical interventions, but an internationally accepted guideline is lacking. With this study, we aim to better understand how management strategies influence short-term outcome parameters, like length of stay, antibiotic treatment duration, and lung damage. Methods: Retrospective observational single-centre study. Patients admitted from 1 July 2004 to 30 June 2024 with PPE to our tertiary hospital were analysed. We used the exact Jonckheere-Terpstra test to analyse trends over time. Results: A total of 278 patients were included, 23 (8%) had to be excluded for lack of informed consent. A majority (173/255, 68%) were treated with pleural drainage. Over time, drains were increasingly more often inserted without surgery, 20% vs. 65% ( p = 0.001) in 2004–2008 vs. 2020–2024. Intravenous antibiotic treatment duration declined from 15 days in 2004–2008 to 11 days in 2020–2024, p = 0.002. The most commonly identified pathogen was S. pneumoniae (39%), followed by S. pyogenes (18%). S. pyogenes compared to S. pneumoniae was more often associated with sepsis or toxic shock (45% vs. 6%, p < 0.0001), but fewer patients showed radiologic evidence for acute lung damage (68% vs. 23%, p < 0.001). Conclusion: We found considerable clinical differences in patients with PPE caused by S. pneumoniae vs. S. pyogenes. The former was associated with substantially greater lung damage.
- 14 October 2025
- Published by Springer Nature in Infection
- Vol. 54 (1) , 287-297
Open AccessPaediatric parapneumonic effusion – a twenty-year clinical narrative
Purpose: Paediatric parapneumonic effusion (PPE) is accompanied by an increased risk of complications, e.g., sepsis or lung sequelae. Treatment strategies span from antibiotics alone to surgical interventions, but an internationally accepted guideline is lacking. With this study, we aim to better understand how management strategies influence short-term outcome parameters, like length of stay, antibiotic treatment duration, and lung damage. Methods: Retrospective observational single-centre study. Patients admitted from 1 July 2004 to 30 June 2024 with PPE to our tertiary hospital were analysed. We used the exact Jonckheere-Terpstra test to analyse trends over time. Results: A total of 278 patients were included, 23 (8%) had to be excluded for lack of informed consent. A majority (173/255, 68%) were treated with pleural drainage. Over time, drains were increasingly more often inserted without surgery, 20% vs. 65% ( p = 0.001) in 2004–2008 vs. 2020–2024. Intravenous antibiotic treatment duration declined from 15 days in 2004–2008 to 11 days in 2020–2024, p = 0.002. The most commonly identified pathogen was S. pneumoniae (39%), followed by S. pyogenes (18%). S. pyogenes compared to S. pneumoniae was more often associated with sepsis or toxic shock (45% vs. 6%, p < 0.0001), but fewer patients showed radiologic evidence for acute lung damage (68% vs. 23%, p < 0.001). Conclusion: We found considerable clinical differences in patients with PPE caused by S. pneumoniae vs. S. pyogenes. The former was associated with substantially greater lung damage.
- Open Access
- 1 November 2024
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 154 (11) , 3678
Syphilis in pregnant women and congenital syphilis from 2012 to 2021 in Switzerland: a multicentre, retrospective study
BACKGROUND AND AIMS OF THE STUDY: Congenital syphilis is a rare complication of syphilis in pregnant women. Vertical transmission may occur at any time during pregnancy. The incidence of congenital syphilis has been increasing worldwide. Congenital syphilis has been a notifiable disease for many years in Switzerland but reporting does not include maternal features associated with syphilis in pregnancy or infantʼs subsequent development. We described syphilis cases among pregnant women screened over a 10-year period in Switzerland and subsequent cases of congenital syphilis, in order to identify maternal risk profiles and to optimise prevention. Second, we compared the characteristics of pregnant women screened early (1st trimester) vs late in pregnancy (2nd or 3rd trimester). Finally, we assessed the risk factors for premature birth among these women with syphilis. METHODS: A multicentre retrospective study conducted in Swiss hospitals from 2012 to 2021, including pregnant women who screened positive for syphilis (Treponema pallidum haemagglutination assay [TPHA] / T. pallidum particle agglutination assay [TPPA ] ≥1:80) and newborns exposed to T. pallidum in utero and/or congenitally infected and with a positive syphilis serology at birth. Data were collected from medical records. RESULTS: A total of 147 syphilis-positive pregnant women and 102 infants were included. A history of treated syphilis was known for 44% (65/147) of the mothers corresponding to a serological scar and the remaining 56% (82/147) were newly identified syphilis cases. Syphilis screening was done during the first trimester in 54%, second trimester in 29% and third trimester in 13% of cases. Two babies were diagnosed with congenital syphilis (1.96%). Several potential factors that could contribute to women’s risk of syphilis during pregnancy were identified such as a foreign origin (93% of mothers), lack of healthcare insurance (25%), no employment status (37%), drug use (5%), co-infection with other sexually transmitted infections (24%) and a late first antenatal consultation (42%). The number of pregnant women without insurance was higher in women diagnosed in the second or third trimester than in those diagnosed in the first trimester (odds ratio 0.41; 95% CI 0.19–0.89; p = 0.024). Syphilis diagnosed in the second or third trimester was associated with a late first antenatal consultation (odds ratio 77.82; 95% CI 9.81–617.21; p <0.001). A high rate of intrauterine growth retardation and of preterm birth was observed in newborns (18% versus 6% in Switzerland in 2022). CONCLUSION: Congenital syphilis remains rare in Switzerland. However, we found potential maternal factors associated with a positive syphilis serology during pregnancy, which can help to improve future prevention measures. The study protocol was registered on ClinicalTrials.gov (ID NCT05975502).
- 1 November 2024
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 154 (11) , 3678
Open AccessSyphilis in pregnant women and congenital syphilis from 2012 to 2021 in Switzerland: a multicentre, retrospective study
BACKGROUND AND AIMS OF THE STUDY: Congenital syphilis is a rare complication of syphilis in pregnant women. Vertical transmission may occur at any time during pregnancy. The incidence of congenital syphilis has been increasing worldwide. Congenital syphilis has been a notifiable disease for many years in Switzerland but reporting does not include maternal features associated with syphilis in pregnancy or infantʼs subsequent development. We described syphilis cases among pregnant women screened over a 10-year period in Switzerland and subsequent cases of congenital syphilis, in order to identify maternal risk profiles and to optimise prevention. Second, we compared the characteristics of pregnant women screened early (1st trimester) vs late in pregnancy (2nd or 3rd trimester). Finally, we assessed the risk factors for premature birth among these women with syphilis. METHODS: A multicentre retrospective study conducted in Swiss hospitals from 2012 to 2021, including pregnant women who screened positive for syphilis (Treponema pallidum haemagglutination assay [TPHA] / T. pallidum particle agglutination assay [TPPA ] ≥1:80) and newborns exposed to T. pallidum in utero and/or congenitally infected and with a positive syphilis serology at birth. Data were collected from medical records. RESULTS: A total of 147 syphilis-positive pregnant women and 102 infants were included. A history of treated syphilis was known for 44% (65/147) of the mothers corresponding to a serological scar and the remaining 56% (82/147) were newly identified syphilis cases. Syphilis screening was done during the first trimester in 54%, second trimester in 29% and third trimester in 13% of cases. Two babies were diagnosed with congenital syphilis (1.96%). Several potential factors that could contribute to women’s risk of syphilis during pregnancy were identified such as a foreign origin (93% of mothers), lack of healthcare insurance (25%), no employment status (37%), drug use (5%), co-infection with other sexually transmitted infections (24%) and a late first antenatal consultation (42%). The number of pregnant women without insurance was higher in women diagnosed in the second or third trimester than in those diagnosed in the first trimester (odds ratio 0.41; 95% CI 0.19–0.89; p = 0.024). Syphilis diagnosed in the second or third trimester was associated with a late first antenatal consultation (odds ratio 77.82; 95% CI 9.81–617.21; p <0.001). A high rate of intrauterine growth retardation and of preterm birth was observed in newborns (18% versus 6% in Switzerland in 2022). CONCLUSION: Congenital syphilis remains rare in Switzerland. However, we found potential maternal factors associated with a positive syphilis serology during pregnancy, which can help to improve future prevention measures. The study protocol was registered on ClinicalTrials.gov (ID NCT05975502).
- Open Access
- 2 September 2024
- Published by MDPI AG in Infectious Disease Reports
- Vol. 16 (5) , 864-869
Ongoing Excess Hospitalizations for Severe Pediatric Group A Streptococcal Disease in 2023–2024—A Single-Center Report
A Europe-wide outbreak of invasive pediatric group A streptococcal infections (iGAS) began in fall 2022. Here, we report the evolution of GAS hospitalizations in children and adolescents during the second outbreak year in 2023–2024 at a tertiary center in Switzerland. Using prospective monitoring of all in-patient GAS cases below 16 years of age, including those with iGAS, we compared case frequencies and clinical characteristics in three time periods (2013–2020; 2022–2023; 2023–2024). Annual GAS hospitalizations increased from a median of 25 cases (range 11–28) in 2013–2020 to 89 and 63 cases, respectively, in 2022–2023 and 2023–2024. iGAS cases evolved similarly (2013–2020, 4 cases (3–8); 2022–2023, 32 cases; 2023–2024, 21 cases). The decline in cases from 2022–2023 to 2023–2024 included all types of GAS organ involvement, except suppurative infections in the head area, which remained largely unchanged (48 vs. 45 cases). Pleural empyema declined from 13 to 7 cases, possibly explained by a poor overlap of the GAS and influenza curves, respectively, in 2023–2024 compared to 2022–2023. These data document the prolongation of the GAS outbreak into its second winter season in 2023–2024.
- 2 September 2024
- Published by MDPI AG in Infectious Disease Reports
- Vol. 16 (5) , 864-869
Open AccessOngoing Excess Hospitalizations for Severe Pediatric Group A Streptococcal Disease in 2023–2024—A Single-Center Report
A Europe-wide outbreak of invasive pediatric group A streptococcal infections (iGAS) began in fall 2022. Here, we report the evolution of GAS hospitalizations in children and adolescents during the second outbreak year in 2023–2024 at a tertiary center in Switzerland. Using prospective monitoring of all in-patient GAS cases below 16 years of age, including those with iGAS, we compared case frequencies and clinical characteristics in three time periods (2013–2020; 2022–2023; 2023–2024). Annual GAS hospitalizations increased from a median of 25 cases (range 11–28) in 2013–2020 to 89 and 63 cases, respectively, in 2022–2023 and 2023–2024. iGAS cases evolved similarly (2013–2020, 4 cases (3–8); 2022–2023, 32 cases; 2023–2024, 21 cases). The decline in cases from 2022–2023 to 2023–2024 included all types of GAS organ involvement, except suppurative infections in the head area, which remained largely unchanged (48 vs. 45 cases). Pleural empyema declined from 13 to 7 cases, possibly explained by a poor overlap of the GAS and influenza curves, respectively, in 2023–2024 compared to 2022–2023. These data document the prolongation of the GAS outbreak into its second winter season in 2023–2024.
- Open Access
- 18 July 2024
- Published by MDPI AG in Preprints.org
Ongoing Excess Hospitalizations for Severe Pediatric Group a Streptococcal Disease in 2023–2024 – a Single Center Report
A Europe-wide outbreak of invasive pediatric Group a streptococcal infections (iGAS) began in fall 2022. Here we report the evolution of GAS hospitalizations in children and adolescents during the second outbreak year in 2023-2024 at a tertiary center in Switzerland. Using prospective monitoring of all in-patient GAS cases below 16 years of age including those with iGAS, we compared case frequencies and clinical characteristics in three time periods (2013-2020; 2022-2023; 2023-2024). Annual GAS hospitalizations increased from a median of 25 case (range 11-28) in 2013-2020 to 89 and 63 cases, respectively, in 2022-2023 and 2023-2024. iGAS cases evolved similarly (2013-2020, 4 cases (3-8); 2022-2023, 32 cases; 2023-2024, 21 cases). The decline in cases from 2022-2023 to 2023-2024 included all types of GAS organ involvement except suppurative infections in the head area, which remained largely unchanged (48 vs. 45 cases). Pleural empyema declined from 13 to 7 cases, possibly explained by a poor overlap of the GAS and influenza curves, respectively, in 2023-2024 compared to 2022-2023. These data document the prolongation of the GAS outbreak into its second winter season in 2023-2024, however with a decline of iGAS, pleural empyema, skin and soft tissue infection and infections of bone, joint and muscle.
- 18 July 2024
- Published by MDPI AG in Preprints.org
Open AccessOngoing Excess Hospitalizations for Severe Pediatric Group a Streptococcal Disease in 2023–2024 – a Single Center Report
A Europe-wide outbreak of invasive pediatric Group a streptococcal infections (iGAS) began in fall 2022. Here we report the evolution of GAS hospitalizations in children and adolescents during the second outbreak year in 2023-2024 at a tertiary center in Switzerland. Using prospective monitoring of all in-patient GAS cases below 16 years of age including those with iGAS, we compared case frequencies and clinical characteristics in three time periods (2013-2020; 2022-2023; 2023-2024). Annual GAS hospitalizations increased from a median of 25 case (range 11-28) in 2013-2020 to 89 and 63 cases, respectively, in 2022-2023 and 2023-2024. iGAS cases evolved similarly (2013-2020, 4 cases (3-8); 2022-2023, 32 cases; 2023-2024, 21 cases). The decline in cases from 2022-2023 to 2023-2024 included all types of GAS organ involvement except suppurative infections in the head area, which remained largely unchanged (48 vs. 45 cases). Pleural empyema declined from 13 to 7 cases, possibly explained by a poor overlap of the GAS and influenza curves, respectively, in 2023-2024 compared to 2022-2023. These data document the prolongation of the GAS outbreak into its second winter season in 2023-2024, however with a decline of iGAS, pleural empyema, skin and soft tissue infection and infections of bone, joint and muscle.
- Open Access
Swissped-RECOVERY: masked independent adjudication for the interpretation of non-randomised treatment in a two-arm open-label randomised controlled trial (methylprednisolone vs immunoglobulins) in Paediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS) involving 10 secondary and tertiary paediatric hospitals in Switzerland
Objectives In trials of acute severe infections or inflammations frequent administration of non-randomised treatment (ie, intercurrent event) in response to clinical events is expected. These events may affect the interpretation of trial findings. Swissped-RECOVERY was set up as one of the first randomised controlled trials worldwide, investigating the comparative effectiveness of anti-inflammatory treatment with intravenous methylprednisolone or intravenous immunoglobulins in children and adolescents with Paediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS). We present one approach towards improving the interpretation of non-randomised treatment in a randomised controlled trial. Design This is a pre-planned ancillary analysis of the Swissped-RECOVERY trial, a randomised multicentre open-label two-arm trial. Setting 10 Swiss paediatric hospitals (secondary and tertiary care) participated. Participants Paediatric patients hospitalised with PIMS-TS. Interventions All patient-first intercurrent events, if applicable, were presented to an independent adjudication committee consisting of four international paediatric COVID-19 experts to provide independent clinical adjudication to a set of standardised questions relating to whether additional non-randomised treatments were clinically indicated and disease classification at the time of the intercurrent event. Results Of 41 treatments in 75 participants (24/41 (59%) and 17/41 (41%) in the intravenous methylprednisolone and immunoglobulin arms of the trial, respectively), two-thirds were considered indicated. The most common treatment (oral glucocorticoids, 14/41, 35%) was mostly considered not indicated (11/14, 79%), although in line with local guidelines. Intercurrent events among patients with Shock-like PIMS-TS at baseline were mostly considered indicated. A significant proportion of patients with undifferentiated PIMS-TS at baseline were not attributed to the same group at the time of the intercurrent event (6/12 unchanged, 4/12 Kawasaki disease-like, 2/12 Shock-like). Conclusion The masked adjudication of intercurrent events contributes to the interpretation of results in open-label trials and should be incorporated in the future. Trial registration numbers SNCTP000004720 and NCT 04826588.
Open AccessSwissped-RECOVERY: masked independent adjudication for the interpretation of non-randomised treatment in a two-arm open-label randomised controlled trial (methylprednisolone vs immunoglobulins) in Paediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS) involving 10 secondary and tertiary paediatric hospitals in Switzerland
Objectives In trials of acute severe infections or inflammations frequent administration of non-randomised treatment (ie, intercurrent event) in response to clinical events is expected. These events may affect the interpretation of trial findings. Swissped-RECOVERY was set up as one of the first randomised controlled trials worldwide, investigating the comparative effectiveness of anti-inflammatory treatment with intravenous methylprednisolone or intravenous immunoglobulins in children and adolescents with Paediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS). We present one approach towards improving the interpretation of non-randomised treatment in a randomised controlled trial. Design This is a pre-planned ancillary analysis of the Swissped-RECOVERY trial, a randomised multicentre open-label two-arm trial. Setting 10 Swiss paediatric hospitals (secondary and tertiary care) participated. Participants Paediatric patients hospitalised with PIMS-TS. Interventions All patient-first intercurrent events, if applicable, were presented to an independent adjudication committee consisting of four international paediatric COVID-19 experts to provide independent clinical adjudication to a set of standardised questions relating to whether additional non-randomised treatments were clinically indicated and disease classification at the time of the intercurrent event. Results Of 41 treatments in 75 participants (24/41 (59%) and 17/41 (41%) in the intravenous methylprednisolone and immunoglobulin arms of the trial, respectively), two-thirds were considered indicated. The most common treatment (oral glucocorticoids, 14/41, 35%) was mostly considered not indicated (11/14, 79%), although in line with local guidelines. Intercurrent events among patients with Shock-like PIMS-TS at baseline were mostly considered indicated. A significant proportion of patients with undifferentiated PIMS-TS at baseline were not attributed to the same group at the time of the intercurrent event (6/12 unchanged, 4/12 Kawasaki disease-like, 2/12 Shock-like). Conclusion The masked adjudication of intercurrent events contributes to the interpretation of results in open-label trials and should be incorporated in the future. Trial registration numbers SNCTP000004720 and NCT 04826588.
- Open Access
- 1 March 2024
- Published by Springer Nature in Infection
- Vol. 52 (4) , 1397-1405
Preadmission course and management of severe pediatric group A streptococcal infections during the 2022–2023 outbreak: a single-center experience
Purpose: The massive increase of infections with Group A Streptococcus (GAS) in 2022–2023 coincided in Switzerland with a change of the recommendations for the management of GAS pharyngitis. Therefore, the objective of the present study was to investigate whether the clinical manifestations and management before hospitalization for GAS infection differed in 2022–2023 compared with 2013–2022. Methods: Retrospective study of GAS infections requiring hospitalization in patients below 16 years. Preadmission illness (modified McIsaac score), oral antibiotic use, and outcome in 2022–2023 were compared with 2013–2022. Time series were compared with surveillance data for respiratory viruses. Results: In 2022–2023, the median modified McIsaac score was lower (2 [IQR 2–3] vs. 3 [IQR 2–4], p = < 0.0001) and the duration of preadmission illness was longer (4 days [3–7] vs. 3 [2–6], p = 0.004) than in 2013–2022. In both periods, withholding of preadmission oral antibiotics despite a modified McIsaac score ≥ 3 (12% vs. 18%, n.s.) or ≥ 4 (2.4% vs. 10.0%, p = 0.027) was rare. Respiratory disease, skeletal/muscle infection, and invasive GAS disease were significantly more frequent in 2022–2023, but there were no differences in clinical outcome. The time course of GAS cases in 2022–2023 coincided with the activity of influenza A/B. Conclusion: We found no evidence supporting the hypothesis that the 2022–2023 GAS outbreak was associated with a change in preadmission management possibly induced by the new recommendation for GAS pharyngitis. However, clinical manifestations before admission and comparative examination of time-series strongly suggest that viral co-circulation played an important role in this outbreak.
- 1 March 2024
- Published by Springer Nature in Infection
- Vol. 52 (4) , 1397-1405
Open AccessPreadmission course and management of severe pediatric group A streptococcal infections during the 2022–2023 outbreak: a single-center experience
Purpose: The massive increase of infections with Group A Streptococcus (GAS) in 2022–2023 coincided in Switzerland with a change of the recommendations for the management of GAS pharyngitis. Therefore, the objective of the present study was to investigate whether the clinical manifestations and management before hospitalization for GAS infection differed in 2022–2023 compared with 2013–2022. Methods: Retrospective study of GAS infections requiring hospitalization in patients below 16 years. Preadmission illness (modified McIsaac score), oral antibiotic use, and outcome in 2022–2023 were compared with 2013–2022. Time series were compared with surveillance data for respiratory viruses. Results: In 2022–2023, the median modified McIsaac score was lower (2 [IQR 2–3] vs. 3 [IQR 2–4], p = < 0.0001) and the duration of preadmission illness was longer (4 days [3–7] vs. 3 [2–6], p = 0.004) than in 2013–2022. In both periods, withholding of preadmission oral antibiotics despite a modified McIsaac score ≥ 3 (12% vs. 18%, n.s.) or ≥ 4 (2.4% vs. 10.0%, p = 0.027) was rare. Respiratory disease, skeletal/muscle infection, and invasive GAS disease were significantly more frequent in 2022–2023, but there were no differences in clinical outcome. The time course of GAS cases in 2022–2023 coincided with the activity of influenza A/B. Conclusion: We found no evidence supporting the hypothesis that the 2022–2023 GAS outbreak was associated with a change in preadmission management possibly induced by the new recommendation for GAS pharyngitis. However, clinical manifestations before admission and comparative examination of time-series strongly suggest that viral co-circulation played an important role in this outbreak.
- Open Access
- 15 January 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (4) , 361-364
COVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children
Data on COVID-19 vaccine acceptability among parents of children with multisystem inflammatory syndrome (MIS-C) are limited. In this cohort of children with MIS-C, enrolled in the Swissped RECOVERY trial (NCT 04826588), comparing intravenous immunoglobulins or methylprednisolone, who, in accordance with Swiss guidelines, were recommended for SARS-CoV-2 vaccination, 65% (73/112) of parents reported being vaccinated against SARS-CoV-2 before the MIS-C, while 70% were vaccinated after the MIS-C episode of their child. None of the children were vaccinated before the occurrence of the MIS-C, and only 9% (5/56) received the COVID-19 vaccine after the MIS-C. The predominant barriers to COVID-19 vaccination were concerns over potential side effects and insufficient support from their doctors. This emphasizes the crucial role of health care providers in promoting COVID-19 vaccination among children.
- 15 January 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (4) , 361-364
Open AccessCOVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children
Data on COVID-19 vaccine acceptability among parents of children with multisystem inflammatory syndrome (MIS-C) are limited. In this cohort of children with MIS-C, enrolled in the Swissped RECOVERY trial (NCT 04826588), comparing intravenous immunoglobulins or methylprednisolone, who, in accordance with Swiss guidelines, were recommended for SARS-CoV-2 vaccination, 65% (73/112) of parents reported being vaccinated against SARS-CoV-2 before the MIS-C, while 70% were vaccinated after the MIS-C episode of their child. None of the children were vaccinated before the occurrence of the MIS-C, and only 9% (5/56) received the COVID-19 vaccine after the MIS-C. The predominant barriers to COVID-19 vaccination were concerns over potential side effects and insufficient support from their doctors. This emphasizes the crucial role of health care providers in promoting COVID-19 vaccination among children.